Publications by authors named "M A Zarbin"
Article Synopsis
- The study aimed to identify demographic factors and health conditions that increase the risk of developing endogenous endophthalmitis (EE) in patients with infective endocarditis (IE).
- Analysis of data from 769,472 inpatient cases revealed that older patients (21-64 years) and those identifying as Hispanic or Asian/Pacific Islander had a higher risk of EE, while women made up a slightly higher percentage of EE patients.
- Diabetes (both with and without complications), alcohol use disorder, and cirrhosis were linked to a significantly increased risk of EE, while congestive heart failure and arrhythmia were associated with a lower risk.
Article Synopsis
- The study looked at how well a treatment called intravitreal methotrexate (MTX) worked for patients with a serious eye problem called retinal detachment.
- They checked the medical records of 21 patients who received this treatment after surgery to help them see better.
- The results showed that 90% of the patients had successful surgery to fix their eye, but 33% had some minor eye issues afterward.
Purpose: Diabetic Retinopathy Clinical Research Network Protocol T suggests that the response to treatment among patients with diabetic macular edema (DME) may vary depending on baseline best-corrected visual acuity (BCVA). We evaluated the efficacy of faricimab 6 mg versus aflibercept 2 mg over 2 years in patients with DME and baseline BCVA of 20/50 or worse enrolled in faricimab phase III trials.
Design: YOSEMITE and RHINE were identically designed, multicenter, randomized, double-masked, active comparator-controlled, noninferiority trials.
Introduction: To assess real-world safety outcomes for adults with neovascular age-related macular degeneration (nAMD) treated with brolucizumab from the US-based IRIS® (Intelligent Research in Sight) Registry.
Methods: In this retrospective study, 18,312 eyes (15,998 patients) treated with ≥ 1 intravitreal brolucizumab injections between 8 October 2019 (US launch date for brolucizumab) and 7 October 2021 were followed up for ≤ 2 years after first injection (index date). The study assessed the predefined incident ocular adverse events of intraocular inflammation (IOI), retinal vasculitis (RV), and retinal vascular occlusion (RO).